Synthesis and Cytoxicity of a TAT Peptide Doxorubicin Conjugate for Breast Cancer Treatment

2015-01-01
Gülseren Petek, Şen
Yalçın Azarkan, Serap
Gündüz, Ufuk
The TAT peptide is a drug delivery tools which has been efficiently proven to deliver drugs, peptides and nucleic acids. A specific sequence of HIV1 protein transduction domain TAT was evaluated for its ability to carry Doxorubicin (Dox) into drug resistant MCF-7 tumor cells. TAT was conjugated to Dox via the formation of a disulfide bond. In this study, we developed an optimal formulation for the conjugation of Dox by this delivery system for tumor treatment. The in vitro study showed that DoxTAT peptide conjugate was only more potent than free drug at higher concentration on Dox resistance cells. The concentration of drug in resistant cancer cells was increased indicating a partial reversal of drug resistance.
Citation Formats
Ş. Gülseren Petek, S. Yalçın Azarkan, and U. Gündüz, “Synthesis and Cytoxicity of a TAT Peptide Doxorubicin Conjugate for Breast Cancer Treatment,” pp. 1007–1007, 2015, Accessed: 00, 2021. [Online]. Available: https://hdl.handle.net/11511/85661.